Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Prepaid Assets (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Prepaid Assets for 11 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 294.5% year-over-year to $21.2 million, compared with a TTM value of $21.2 million through Dec 2025, up 294.5%, and an annual FY2025 reading of $21.2 million, up 294.5% over the prior year.
  • Prepaid Assets was $21.2 million for Q4 2025 at Spyre Therapeutics, up from $18.4 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $21.2 million in Q4 2025 and bottomed at $2.2 million in Q3 2023.
  • Average Prepaid Assets over 5 years is $7.0 million, with a median of $5.5 million recorded in 2023.
  • The sharpest move saw Prepaid Assets crashed 72.23% in 2023, then soared 294.5% in 2025.
  • Year by year, Prepaid Assets stood at $4.9 million in 2021, then rose by 24.74% to $6.2 million in 2022, then plummeted by 63.53% to $2.3 million in 2023, then soared by 139.27% to $5.4 million in 2024, then skyrocketed by 294.5% to $21.2 million in 2025.
  • Business Quant data shows Prepaid Assets for SYRE at $21.2 million in Q4 2025, $18.4 million in Q3 2025, and $12.3 million in Q2 2025.